GalletlyCACastleDJDarkF, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry2016; 50: 410–472.
2.
GalletlyCAFoleyDLWaterreusA, et al. Cardiometabolic risk factors in people with psychotic disorders: the second Australian national survey of psychosis. Aust N Z J Psychiatry2012; 46: 753–761.
3.
AlbertiKGEckelRHGrundySM, et al. Harmonizing the metabolic syndrome. Circulation2009; 120: 1640–1645.
4.
DekkerJMGirmanCRhodesT, et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation2005; 112: 666–673.
5.
MotillioSFilionKBGenestJ, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol2010; 56: 1113–1132.
6.
CastleDJChungE.Cardiometabolic comorbidities and life expectancy in people on medication for schizophrenia in Australia. Curr Med Res Opin2018; 34: 613–618.
7.
LaursenTM.Life expectancy among persons with schizophrenia or bipolar affective disorder. Schizophr Res2011; 131: 101–104.
8.
De HertMDetrauxJvan WinkelR, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol2011; 18: 114–126.
9.
LaugharneJWaterreusAJCastleDJ, et al. Screening for the metabolic syndrome in Australia: a national survey of psychiatrists’ attitudes and reported practice in patients prescribed antipsychotic drugs. Australas Psychiatry2016; 24: 62–66.
10.
HuhnMNikolakopoulouASchneider-ThomaJ, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet2019; 394: 939–951.
11.
PillingerTMcCutcheonRAVanoL, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiat2020; 7: 64–77.
12.
GregerJAladeenTLewandowskiE, et al. Comparison of the metabolic characteristics of newer second generation antipsychotics: brexpiprazole, lurasidone, asenapine, cariprazine, and iloperidone with olanzapine as a comparator. J Clin Psychopharmacol [In Press].
13.
MorganVAWaterreusAJablenskyA, et al. People living with psychotic illness in 2010: the second Australian national survey of psychosis. Aust N Z J Psychiatry2012; 46: 735–752.
